Calcitonin Gene-Related Peptide-Targeted Therapy in Migraine: Current Role and Future Perspectives
Lancet 405:1014-1026, Versijpt,J.,et al, 2025
Efficacy and Safety of Erenumab for Nonopioid Medication Overuse Headache in Chronic Migraine, A Phase 4, Randomized, Placebo-Controlled Trial
JAMA Neurol 81:1140-1149, Tepper,S.J.,et al, 2024
Lecanemab in Early Alzheimers Disease
NEJM 388:9-21,80, van Dyck,A.H.,et al, 2023
Atogepant for the Preventive Treatment of Chronic Migraine (PROGRESS): A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial
Lancet 402:775-785, Pozo-Rosich,P.,et al, 2023
Lenvatinib Therapy for Advanced Thyroid Cancer: Real-Life Data on Safety, Efficacy, and Some Rare Side Effects
JENDSO 6:1-7, Hamidi, S.,et al, 2022
Acute Treatment for Migraine
JAMA 325:2346-2347, Burch, R. & Rayhill, M., 2021
Atogepant for the Preventive Treatment of Migraine
NEJM 385:695-706, Ailani,J.,et al, 2021
Teleneurology
Pract Neurol 19:13, Gollomp, S. & Mathew, P.G., 2020
Remigepant, an Oral Calcitonin Gene-Related Peptide Receptor Antagonist, for Migraine
NEJM 381:142-149, Lipton, R.B.,et al, 2019
Trial of Galcanezumab in Prevention of Episodic Cluster Headache
NEJM 381:132-141, Goadsby, P.J.,et al, 2019
Fremanezumab versus Placebo for Migraine Prevention in Patients with Documented Failure to Up to Four Migraine Preventive Medication Classes (FOCUS): A Randomised, Double-Blind, Placebo-Controlled, Phase 3� Trial
Lancet 394:1030-1040, Ferrari, M.D.,et al, 2019
Targeting Calcitonin Gene-Related Peptide: A New Era in Migraine Therapy
Lancet 394:1765-1774, Charles, A. & Pozo-Rosich, P., 2019
Ubrogepant for the Treatment of Migraine
NEJM 381:2230-2241, Dodick, D.W.,et al, 2019
Aminophylline for treatment of postdural puncture headache
Neurol 90:e1523-e1529, Wu, C.,et al, 2018
Noninvasive Vagus Nerve Stimulation as Acute Therapy for Migraine
Neurol 91:e364-e373, Tassorelli,C., et al, 2018
Efficacy and Tolerability of Erenumab in Patients with Episodic Migraine in Whom Two-of-Four Previous Preventive Treatments were Unsuccessful: A Randomised, Double-Blind, Placebo-Controlled, Phase 3b Study
Lancet 392:2280-2287,2241, Reuter, U.,et al, 2018
Galcanezumab in Chronic Migraine
Neurol 91:e2211-e2221, Detke, H.C.,et al, 2018
Lasmiditan is an Effective Acute Treatment for Migraine
Neurol 91:e2222-e2232, Kuca, B.,et al, 2018
A Randomized Trial of Telemedicine Efficacy and Safety for Nonacute Headaches
Neurol 89:153-162, Muller, K.I.,et al, 2017
CGRP - The Next Frontier for Migraine
NEJM 377:2190-2191, Hershey, A.D., 2017
Evidence-Based Treatments for Adults with Migraine
Pain Reser Treat 2015:DOI:10.1155/2015/629382, Gooriah, R.,et al, 2015
Triptans for Symptomatic Treatment of Migraine Headache
BMJ 348:g2285, Pringsheim, T. & Becker, W.J., 2014
Systematic Review: Efficacy and Safety of Medical Marijuana in Selected Neurologic Disorders
Neurol 82:1556-1563, Koppel, B.S.,et al, 2014
MR Myelography for Identification of Spinal CSF Leak in Spontaneous Intracranial Hypotension
AJNR 35:2007-2012, Chazen, J.L.,et al, 2014
OnabotulinumtoxinA Improves Quality of Life and Reduces Impact of Chronic Migraine
Neurol 77:1465-1472, Lipton, R.B.,et al, 2011
Intravenous Dihydroergotamine for Inpatient Management of Refractory Primary Headaches
Neurol 77:1827-1832, Nagy, A.J.,et al, 2011
Tricyclic Antidepressants and Headaches: Systematic Review and Meta-Analysis
BMJ 341:c5222, Jackson,J.L.,et al, 2010
Oxcarbazepine in Migraine Headache: A Double-Blind, Randomized, Placebo-Controlled Study
Neurol 70:548-555, Silberstein,S.,et al, 2008
Treatment of Medically Intractable Cluster Headache by Occipital Nerve Stimulation: Long-Term Follow-Up of Eight Patients
Lancet 369:1099-1065, Burns,B.,et al, 2007
Sumatriptan-Naproxen for Acute Treatment of Migraine, A Randomized Trial
JAMA 297:1443-1454, Brandes,J.L.,et al, 2007
Neurological Complications With Acute Sphenoid Sinusitis a Surgical Emergency?
Neurocrit Care 7:169-171, Poulopoulos,M. &Finelli,P.F., 2007
Zolmitriptan Nasal Spray in the Acute Treatment of Cluster Headache: A Double-Blind Study
Neurol 69:821-826, Rapoport,A.M.,et al, 2007
Treatment of Childhood Migraine Attacks With Oral Zomitriptan and Ibuprofen
Neurol 67:497-499, Evers,S.,et al, 2006
A Randomized Trial of Tenecteplase in Acute Central Retinal Artery Occlusion
NEJM 394:442-450, Ryan,S.J.,et al, 2026
Zorevunersen in Children and Adolescents with Dravet Syndrome
NEJM 394:969-982, Laux,L.,et al, 2026
Asundexian for Secondary Stroke Prevention
NEJM 394:1467-1479, 1540, Sharm,M.,et al, 2026
Large Language Model Performance and Clinical Reasoning Tasks
JAMA Netw Open 9:e264003, Rao,A.S.,et al, 2026
Endovascular Venous Sinus Stenting versus CSF Shunting for Idiopathic Intracranial Hypertssion:Nationwide Real-World Outcomes
AJNR 47:1238-1243, Chen,H.,et al, 2026
Safety and Outcomes of Dibigatran Reversal with Idarucizumab Before IV Thrombolysis in Patients with Acute Ischemic Stroke
Neurol 106:e218012, Saflund,M.,et al, 2026
Efficacy and Safety of IV Thrombolysis for Acute Ischemic Stroke Patients with Moyamoya Disease
Neurol 104:e210243, Chen,H.,et al, 2025
Amyloid-Related Imaging Abnormalities (ARIA) in Clinical Trials of Gantenerumab in Early Alzheimer Disease
JAMA Neurol 92:19-29, Salloway,S.,et al, 2025
FUTURE-AI: International Consensus Guideline for Trustworthy and Deployable Artificial Intelligence in Healthcare
BMJ 388:e081554, Lekadir,K.,et al, 2025
Commonly Used Interventional Procedures for Non-Cancer Chronic Spine Pain: A Clinical Practice Guideline
BMJ 388:e079970, Busse,J.W.,et al, 2025
Embolization of the Middle Meningeal Artery for Chronic Subdural Hematoma
NEJM 392:855-864, 918, Fiorella,D.,et al, 2025
Inebilizumab for Treatment of IgG4-Related Disease
NEJM 392:1168-1177, Stone,J.H.,et al, 2025
Beyond Glucocorticoids for IgG4-Related Disease
NEJM 392:1232-1233, Spiera,R., 2025
Alteplase for Posterior Circulation Ischemic Stropke at 4.5 to 24 Hours
NEJM 392:1288-1296, Yan,S.,et al, 2025
Left Atrial Appendage Closure After Ablation for Atrial Fibrillation
NEJM 392:1277-1287, Wazni,O.M.,et al, 2025
Long-Term Effects of Antidarsagene Autotemcel for Metachromatic Leukodystrophy
NEJM 392:1609-1620, Fumagalli,F.,et al, 2025